TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the Level of Dietary Protein on Infant Growth and Body Composition in the First Year of Life - Three and Five Year Growth and Body Composition Follow-up
Brief Summary: The purpose of this study is to determine if toddlers and children who were fed breast milk or infant formulas at different levels of protein between 3 and 12 months of age have differences in growth and body composition at 3 and 5 years of age.


Options:
A: Arm Label: Infant Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Infant Formula | Arm Label: Breast Milk; Type: OTHER; Interventions: Dietary Supplement: breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Infant Formula; Assigned to Arm(s): Infant Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: breast milk; Assigned to Arm(s): Breast Milk
B: Arm Label: Breast Fed reference group; Type: N/A; Interventions: N/A | Arm Label: Infant formula - protein level 1; Type: N/A; Interventions: N/A | Arm Label: Infant formula - protein level 2; Type: N/A; Interventions: N/A
C: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
D: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Other: Modified infant formula | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard infant formula | Arm Label: Breast-fed Reference Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Modified infant formula; Assigned to Arm(s): Experimental Group | Intervention Type: OTHER; Name: Standard infant formula; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Brief Summary: The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis


Options:
A: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
B: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
C: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Brief Summary: The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700
C: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest of a Steroid Pre-treatment Prior to IVF Protocol With Ovarian Stimulation by Recombinant FSH and With LH Surge Blockage by Daily GnRH Antagonist
Brief Summary: The purpose of this study is to assess whether estrogen pre-treatment can allow retrieval of 2 additional oocytes in GnRH antagonist protocol.


Options:
A: Arm Label: Estrogen pre-treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17beta-estradiol | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 17beta-estradiol; Assigned to Arm(s): Estrogen pre-treatment
B: Arm Label: Oral Contraceptive; Type: ACTIVE_COMPARATOR; Interventions: Drug: Marvelon | Arm Label: Non-Oral Contraceptive; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Marvelon; Assigned to Arm(s): Oral Contraceptive
C: Arm Label: 150 µg Corifollitropin Alfa; Type: EXPERIMENTAL; Interventions: Drug: Corifollitropin alfa, Drug: Placebo RecFSH / follitropin beta, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Arm Label: 200 IU recFSH; Type: ACTIVE_COMPARATOR; Interventions: Biological: RecFSH / Follitropin beta (Days 1 to 7), Drug: Placebo Corifollitropin alfa, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Intervention Type: DRUG; Name: Corifollitropin alfa; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 1 to 7); Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo Corifollitropin alfa; Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo RecFSH / follitropin beta; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 8 to hCG); Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: DRUG; Name: Ganirelix; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: hCG; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: Progesterone; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH
D: Arm Label: natural cycle; Type: OTHER; Interventions: Other: embryo transfer | Arm Label: hormonal cycle; Type: ACTIVE_COMPARATOR; Interventions: Other: embryo transfer | Intervention Type: OTHER; Name: embryo transfer; Assigned to Arm(s): hormonal cycle, natural cycle

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes
Brief Summary: Adolescents with type 1 diabetes are at increased risk for depressive symptoms, poor coping and problem-solving skills, poor regimen adherence, and negative diabetes-specific health outcomes. Although a handful of psychological interventions targeting adolescents' poor behavioral and emotional functioning demonstrate beneficial effects on disease management and outcomes, no prevention programs exist that equip adolescents with behavioral skills and cognitive strategies necessary to reduce these risks. Therefore, the proposed research will test whether a diabetes-specific adaptation of a resilience promoting, depression-prevention intervention for adolescents with type 1 diabetes will reduce both the risk of poor psychological functioning and the risk of negative health outcomes over time.


Options:
A: Arm Label: Citalopram; Type: EXPERIMENTAL; Interventions: Drug: 20mg daily citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 20mg daily citalopram; Assigned to Arm(s): Citalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A
C: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
D: Arm Label: Healthy Thinking in Teens; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Thinking In Teens | Arm Label: Advanced Diabetes Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Advanced Diabetes Education. | Intervention Type: BEHAVIORAL; Name: Healthy Thinking In Teens; Assigned to Arm(s): Healthy Thinking in Teens | Intervention Type: OTHER; Name: Advanced Diabetes Education.; Assigned to Arm(s): Advanced Diabetes Education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Functional Rehabilitation Therapy in Patients Undergoing Physiotherapy After Total Hip Arthroplasty
Brief Summary: This study aims to objectively evaluate the implications of physiotherapeutic rehabilitation in the Assistance Protocol of Total Hip Arthroplasty (THA), by assessing the motor performance and testing the quality of life of patients undergoing THA surgery, to improve rehabilitation strategies for this population.


Options:
A: Arm Label: etomidate/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/propofol; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Intervention Type: OTHER; Name: control; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: suggestion; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: dreamfilm; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane
B: Arm Label: Cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Cognitive behavioral therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stress reduction intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress reduction intervention; Assigned to Arm(s): 1
D: Arm Label: THA Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: THA Physiotherapy, Procedure: No physiotherapy after THA | Arm Label: No physiotherapy after THA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No physiotherapy after THA | Intervention Type: PROCEDURE; Name: THA Physiotherapy; Assigned to Arm(s): THA Physiotherapy | Intervention Type: PROCEDURE; Name: No physiotherapy after THA; Assigned to Arm(s): No physiotherapy after THA, THA Physiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
Brief Summary: AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Options:
A: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
D: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
Brief Summary: AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Options:
A: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
D: Arm Label: OMEGA-3; Type: ACTIVE_COMPARATOR; Interventions: Drug: OMEGA-3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo soybean oil | Intervention Type: DRUG; Name: OMEGA-3; Assigned to Arm(s): OMEGA-3 | Intervention Type: DRUG; Name: Placebo soybean oil; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
Brief Summary: AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
C: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
Brief Summary: AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Options:
A: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
B: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo

Answer: D